Altamira Therapeutics Ltd.
CYTOF
$0.0999
-$0.01-9.10%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.00% | 27.00% | -- | -- | 30.44% |
| Total Depreciation and Amortization | -7.03% | -7.03% | -- | -- | 6.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.23% | -41.23% | -- | -- | 4.68% |
| Change in Net Operating Assets | 111.89% | 111.89% | -- | -- | -320.96% |
| Cash from Operations | 62.00% | 62.00% | -- | -- | -45.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.00% | 200.00% | -- | -- | 100.01% |
| Cash from Investing | 200.00% | 200.00% | -- | -- | 100.01% |
| Total Debt Issued | -- | -- | -- | -- | -45.04% |
| Total Debt Repaid | 57.61% | 57.61% | -- | -- | -204.24% |
| Issuance of Common Stock | -56.12% | -56.12% | -- | -- | 272.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.98% | 68.98% | -- | -- | -2,064.29% |
| Cash from Financing | -70.11% | -70.11% | -- | -- | 23.98% |
| Foreign Exchange rate Adjustments | -64.31% | -64.31% | -- | -- | 250.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,822.16% | -1,822.16% | -- | -- | 106.12% |